Catinazzo Thomas 4

What Happened
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares in an open-market transaction on March 9, 2026. The weighted average sale price was $10.06, producing total proceeds of approximately $178,233. The trades were executed under a Rule 10b5-1 trading plan adopted October 30, 2025.

Key Details

• Transaction type: Sale (Code S) executed in multiple open-market trades on 2026-03-09.
• Price: Weighted average $10.06; individual trade prices ranged from $9.77 to $10.35. (Reporting person can provide per-trade prices on request.)
• Proceeds: ~$178,233.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnotes: F1 = trade pursuant to 10b5-1 plan (10/30/2025). F2 = multiple trades, price range noted. F3 = filing references 13,075 shares underlying restricted stock units (included in reported ownership).
• Filing: Reported on Form 4 filed 2026-03-11 (filed promptly following the 3/9 transaction).

Context
Sales made under a pre-established 10b5-1 trading plan are typically routine and were planned in advance; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases generally carry more weight as a signal than routine insider sales.